The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.
Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer
Open accessAbstract
The tryptophan catabolic enzyme indoleamine 2,3-dioxygenase-1 (IDO1) has attracted enormous attention in driving cancer immunosuppression, neovascularization and metastasis. IDO1 suppresses local CD8+ T effector cells and natural killer cells and induces CD4+ T regulatory cells (iTreg) and myeloid-derived suppressor cells (MDSC). The structurally distinct enzyme tryptophan dioxygenase (TDO) also has been implicated recently in immune escape and metastatic progression. Lastly, emerging evidence suggests that the IDO1-related enzyme IDO2 may support IDO1-mediated iTreg and contribute to B-cell inflammed states in certain cancers. IDO1 and TDO are upregulated widely in neoplastic cells but also variably in stromal, endothelial and innate immune cells of the tumor microenviroment and in tumor-draining lymph nodes. Pharmacological and genetic proofs in preclinical models of cancer have validated IDO1 as a cancer therapeutic target. IDO1 inhibitors have limited activity on their own but greatly enhance ‘immunogenic’ chemotherapy or immune checkpoint drugs. IDO/TDO function is rooted in inflammatory programming, thereby influencing tumor neovascularization, MDSC generation and metastasis beyond effects on adaptive immune tolerance. Discovery and development of small molecule enzyme inhibitors of IDO1 derived from the hydroxylamidine and phenylimidazole chemotypes have advanced furthest to date in Phase II/III human trials (epacadastat and GDC-0919/navoximod, respectively). Second generation combined IDO/TDO inhibitors may broaden impact in cancer treatment, for example, in addressing IDO1 bypass (inherent resistance) or acquired resistance to IDO1 inhibitors. This review surveys knowledge about IDO1 function and how IDO1 inhibitors reprogram inflammation to heighten therapeutic responses in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Prevention of Allogeneic Fetal Rejection by Tryptophan Catabolism
Munn, D. H., Zhou, M., Attwood, J. T., Bondarev, I., Conway, S. J., Marshall, B., Brown, C., & Mellor, A. L. (1998) · Science · doi:10.1126/science.281.5380.1191 · Cited by 2,585
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Opitz, C. A., Litzenburger, U. M., Sahm, F., Ott, M., Tritschler, I., Trump, S., Schumacher, T., Jestaedt, L., Schrenk, D., Weller, M., et al. (2011) · Nature · doi:10.1038/nature10491 · Cited by 1,898
Principles of cancer therapy: oncogene and non-oncogene addiction
Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765
Angiogenesis and Inflammation in Peritoneal Dialysis: The Role of Adipocytes
Shi, J., Yu, M., & Sheng, M. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000476017 · Cited by 1,403
Rodriguez, P. C., Quiceno, D. G., Zabaleta, J., Ortiz, B., Zea, A. H., Piazuelo, M. B., Delgado, A., Correa, P., Brayer, J., Sotomayor, E. M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0465 · Cited by 1,276
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer
Nagaraj, S., Gupta, K., Pisarev, V., Kinarsky, L., Sherman, S., Kang, L., Herber, D. L., Schneck, J., & Gabrilovich, D. I. (2007) · Nature Medicine · doi:10.1038/nm1609 · Cited by 1,174
Muller, A. J., DuHadaway, J. B., Donover, P. S., Sutanto-Ward, E., & Prendergast, G. C. (2005) · Nature Medicine · doi:10.1038/nm1196 · Cited by 1,064
Indoleamine 2,3 dioxygenase and metabolic control of immune responses
Munn, D. H., & Mellor, A. L. (2013) · Trends in Immunology · doi:10.1016/j.it.2012.10.001 · Cited by 1,037
Myeloid-Derived Suppressor Cells Inhibit T-Cell Activation by Depleting Cystine and Cysteine
Srivastava, M. K., Sinha, P., Clements, V. K., Rodriguez, P., & Ostrand-Rosenberg, S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2587 · Cited by 949
The gene encoding the splicing factor SF2/ASF is a proto-oncogene
Karni, R., de Stanchina, E., Lowe, S. W., Sinha, R., Mu, D., & Krainer, A. R. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1209 · Cited by 934
Munn, D. H., Sharma, M. D., Hou, D., Baban, B., Lee, J. R., Antonia, S. J., Messina, J. L., Chandler, P., Koni, P. A., & Mellor, A. L. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21583 · Cited by 852
Sinha, P., Clements, V. K., Bunt, S. K., Albelda, S. M., & Ostrand-Rosenberg, S. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.2.977 · Cited by 847
Tryptophan Catabolism in Cancer: Beyond IDO and Tryptophan Depletion
Platten, M., Wick, W., & Van den Eynde, B. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0569 · Cited by 703
Nguyen, N. T., Kimura, A., Nakahama, T., Chinen, I., Masuda, K., Nohara, K., Fujii-Kuriyama, Y., & Kishimoto, T. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014465107 · Cited by 685
Aryl hydrocarbon receptor control of a disease tolerance defence pathway
Bessede, A., Gargaro, M., Pallotta, M. T., Matino, D., Servillo, G., Brunacci, C., Bicciato, S., Mazza, E. M. C., Macchiarulo, A., Vacca, C., et al. (2014) · Nature · doi:10.1038/nature13323 · Cited by 674
Serafini, P., Mgebroff, S., Noonan, K., & Borrello, I. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6621 · Cited by 673
Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation?
Mellor, A. L., & Munn, D. H. (1999) · Immunology Today · doi:10.1016/s0167-5699(99)01520-0 · Cited by 648
Yu, J., Du, W., Yan, F., Wang, Y., Li, H., Cao, S., Yu, W., Shen, C., Liu, J., & Ren, X. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201449 · Cited by 606
Hou, D.-Y., Muller, A. J., Sharma, M. D., DuHadaway, J., Banerjee, T., Johnson, M., Mellor, A. L., Prendergast, G. C., & Munn, D. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2925 · Cited by 586
Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase
Pilotte, L., Larrieu, P., Stroobant, V., Colau, D., Dolušić, E., Frédérick, R., De Plaen, E., Uyttenhove, C., Wouters, J., Masereel, B., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113873109 · Cited by 572
Spranger, S., Koblish, H. K., Horton, B., Scherle, P. A., Newton, R., & Gajewski, T. F. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-3 · Cited by 552
Self-citationSelective inhibition of IDO1 effectively regulates mediators of antitumor immunity
Liu, X., Shin, N., Koblish, H. K., Yang, G., Wang, Q., Wang, K., Leffet, L., Hansbury, M. J., Thomas, B., Rupar, M., et al. (2010) · Blood · doi:10.1182/blood-2009-09-246124 · Cited by 548
Immune suppressive mechanisms in the tumor microenvironment
Munn, D. H., & Bronte, V. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.10.009 · Cited by 519
Qin, Z., & Blankenstein, T. (2000) · Immunity · doi:10.1016/s1074-7613(00)80218-6 · Cited by 511
Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer
Prendergast, G. C., Smith, C., Thomas, S., Mandik-Nayak, L., Laury-Kleintop, L., Metz, R., & Muller, A. J. (2014) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-014-1549-4 · Cited by 482
Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner
Holmgaard, R. B., Zamarin, D., Li, Y., Gasmi, B., Munn, D. H., Allison, J. P., Merghoub, T., & Wolchok, J. D. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.077 · Cited by 482
Metz, R., DuHadaway, J. B., Kamasani, U., Laury-Kleintop, L., Muller, A. J., & Prendergast, G. C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1872 · Cited by 467
The kynurenine pathway and the brain: Challenges, controversies and promises
Schwarcz, R., & Stone, T. W. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.08.003 · Cited by 461
Sugimoto, H., Oda, S.-I., Otsuki, T., Hino, T., Yoshida, T., & Shiro, Y. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508996103 · Cited by 441
Myeloid-Derived Suppressor Cells Down-Regulate L-Selectin Expression on CD4+ and CD8+ T Cells
Hanson, E. M., Clements, V. K., Sinha, P., Ilkovitch, D., & Ostrand-Rosenberg, S. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804253 · Cited by 427
Metz, R., Rust, S., DuHadaway, J. B., Mautino, M. R., Munn, D. H., Vahanian, N. N., Link, C. J., & Prendergast, G. C. (2012) · OncoImmunology · doi:10.4161/onci.21716 · Cited by 384
Indoleamine 2,3‐dioxygenase contributes to tumor cell evasion of T cell‐mediated rejection
Friberg, M., Jennings, R., Alsarraj, M., Dessureault, S., Cantor, A., Extermann, M., Mellor, A. L., Munn, D. H., & Antonia, S. J. (2002) · International Journal of Cancer · doi:10.1002/ijc.10645 · Cited by 365
Théate, I., van Baren, N., Pilotte, L., Moulin, P., Larrieu, P., Renauld, J.-C., Hervé, C., Gutierrez-Roelens, I., Marbaix, E., Sempoux, C., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0137 · Cited by 363
Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors
Platten, M., von Knebel Doeberitz, N., Oezen, I., Wick, W., & Ochs, K. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00673 · Cited by 340
B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis
Schioppa, T., Moore, R., Thompson, R. G., Rosser, E. C., Kulbe, H., Nedospasov, S., Mauri, C., Coussens, L. M., & Balkwill, F. R. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1100994108 · Cited by 328
Immune escape as a fundamental trait of cancer: focus on IDO
Prendergast, G. C. (2008) · Oncogene · doi:10.1038/onc.2008.35 · Cited by 325
IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development
Smith, C., Chang, M. Y., Parker, K. H., Beury, D. W., DuHadaway, J. B., Flick, H. E., Boulden, J., Sutanto-Ward, E., Soler, A. P., Laury-Kleintop, L. D., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0014 · Cited by 322
Beatty, G. L., O'Dwyer, P. J., Clark, J., Shi, J. G., Bowman, K. J., Scherle, P. A., Newton, R. C., Schaub, R., Maleski, J., Leopold, L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2272 · Cited by 314
Self-citationB Cells Regulate Macrophage Phenotype and Response to Chemotherapy in Squamous Carcinomas
Affara, N. I., Ruffell, B., Medler, T. R., Gunderson, A. J., Johansson, M., Bornstein, S., Bergsland, E., Steinhoff, M., Li, Y., Gong, Q., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.026 · Cited by 304
Aryl hydrocarbon receptor signaling mediates expression of indoleamine 2,3-dioxygenase
Vogel, C. F. A., Goth, S. R., Dong, B., Pessah, I. N., & Matsumura, F. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.07.156 · Cited by 296
Yue, E. W., Sparks, R., Polam, P., Modi, D., Douty, B., Wayland, B., Glass, B., Takvorian, A., Glenn, J., Zhu, W., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00391 · Cited by 295
D'Amato, N. C., Rogers, T. J., Gordon, M. A., Greene, L. I., Cochrane, D. R., Spoelstra, N. S., Nemkov, T. G., D'Alessandro, A., Hansen, K. C., & Richer, J. K. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-2011 · Cited by 294
Induction of pulmonary indoleamine 2,3-dioxygenase by interferon.
Yoshida, R., Imanishi, J., Oku, T., Kishida, T., & Hayaishi, O. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.1.129 · Cited by 292
Cady, S. G., & Sono, M. (1991) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(91)90142-6 · Cited by 285
Kanai, M., Funakoshi, H., Takahashi, H., Hayakawa, T., Mizuno, S., Matsumoto, K., & Nakamura, T. (2009) · Molecular Brain · doi:10.1186/1756-6606-2-8 · Cited by 273
Interleukin-6 Stimulates Defective Angiogenesis
Gopinathan, G., Milagre, C., Pearce, O. M. T., Reynolds, L. E., Hodivala-Dilke, K., Leinster, D. A., Zhong, H., Hollingsworth, R. E., Thompson, R., Whiteford, J. R., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1227 · Cited by 249
Muller, A. J., Sharma, M. D., Chandler, P. R., DuHadaway, J. B., Everhart, M. E., Johnson, B. A., Kahler, D. J., Pihkala, J., Soler, A. P., Munn, D. H., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806173105 · Cited by 240
A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells.
Qin, Z., Schwartzkopff, J., Pradera, F., Kammertoens, T., Seliger, B., Pircher, H., & Blankenstein, T. J. F. (2003) · PubMed · Cited by 235
Leukocytes mediate retinal vascular remodeling during development and vaso-obliteration in disease
Ishida, S., Yamashiro, K., Usui, T., Kaji, Y., Ogura, Y., Hida, T., Honda, Y., Oguchi, Y., & Adamis, A. P. (2003) · Nature Medicine · doi:10.1038/nm877 · Cited by 229
Tryptophan-Degrading Enzymes in Tumoral Immune Resistance
van Baren, N., & Van den Eynde, B. J. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00034 · Cited by 228
Yue, E. W., Douty, B., Wayland, B., Bower, M., Liu, X., Leffet, L., Wang, Q., Bowman, K. J., Hansbury, M. J., Liu, C., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900518f · Cited by 219
Hadji, P., Coleman, R. E., Wilson, C., Powles, T. J., Clézardin, P., Aapro, M., Costa, L., Body, J.-J., Markopoulos, C., Santini, D., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv617 · Cited by 207
Ge, K., DuHadaway, J., Du, W., Herlyn, M., Rodeck, U., & Prendergast, G. C. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.17.9689 · Cited by 195
Metz, R., Smith, C., DuHadaway, J. B., Chandler, P., Baban, B., Merlo, L. M. F., Pigott, E., Keough, M. P., Rust, S., Mellor, A. L., et al. (2014) · International Immunology · doi:10.1093/intimm/dxt073 · Cited by 190
Structure−Activity Study of Brassinin Derivatives as Indoleamine 2,3-Dioxygenase Inhibitors
Gaspari, P., Banerjee, T., Malachowski, W. P., Muller, A. J., Prendergast, G. C., DuHadaway, J., Bennett, S., & Donovan, A. M. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0508888 · Cited by 182
Dolušić, E., Larrieu, P., Moineaux, L., Stroobant, V., Pilotte, L., Colau, D., Pochet, L., Van den Eynde, B., Masereel, B., Wouters, J., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2006782 · Cited by 181
Boyland, E., & Williams, D. C. (1956) · Biochemical Journal · doi:10.1042/bj0640578 · Cited by 180
Xu, Q. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg786 · Cited by 176
Banerjee, T., DuHadaway, J. B., Gaspari, P., Sutanto-Ward, E., Munn, D. H., Mellor, A. L., Malachowski, W. P., Prendergast, G. C., & Muller, A. J. (2008) · Oncogene · doi:10.1038/sj.onc.1210939 · Cited by 175
Soliman, H. H., Jackson, E., Neuger, T., Dees, E. C., Harvey, R. D., Han, H., Ismail-Khan, R., Minton, S., Vahanian, N. N., Link, C., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2357 · Cited by 174
Rational Design of 4-Aryl-1,2,3-Triazoles for Indoleamine 2,3-Dioxygenase 1 Inhibition
Röhrig, U. F., Majjigapu, S. R., Grosdidier, A., Bron, S., Stroobant, V., Pilotte, L., Colau, D., Vogel, P., Van den Eynde, B. J., Zoete, V., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300260v · Cited by 170
Kumar, S., Malachowski, W. P., DuHadaway, J. B., LaLonde, J. M., Carroll, P. J., Jaller, D., Metz, R., Prendergast, G. C., & Muller, A. J. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7014155 · Cited by 169
Nayak-Kapoor, A., Hao, Z., Sadek, R., Dobbins, R., Marshall, L., Vahanian, N. N., Jay Ramsey, W., Kennedy, E., Mautino, M. R., Link, C. J., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0351-9 · Cited by 160
Structure Based Development of Phenylimidazole-Derived Inhibitors of Indoleamine 2,3-Dioxygenase
Kumar, S., Jaller, D., Patel, B., LaLonde, J. M., DuHadaway, J. B., Malachowski, W. P., Prendergast, G. C., & Muller, A. J. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800512z · Cited by 150
A phase I study of indoximod in patients with advanced malignancies
Soliman, H. H., Minton, S. E., Han, H. S., Ismail-Khan, R. R., Neuger, A. M., Khambati, F. A., Noyes, D. R., Lush, R. M., Chiappori, A., Roberts, J. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8216 · Cited by 149
Holmgaard, R., Zamarin, D., Lesokhin, A. M., Merghoub, T., & Wolchok, J. D. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.02.024 · Cited by 148
Genotyping and Expression Analysis of IDO2 in Human Pancreatic Cancer: A Novel, Active Target
Witkiewicz, A. K., Costantino, C. L., Metz, R. A., Muller, A. J., Prendergast, G. C., Yeo, C. J., & Brody, J. R. (2009) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2008.12.018 · Cited by 141
IDO2 in Immunomodulation and Autoimmune Disease
Prendergast, G. C., Metz, R. A., Muller, A. J., Merlo, L. M. F., & Mandik‐Nayak, L. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00585 · Cited by 140
Functional and phenotypic effects of AhR activation in inflammatory dendritic cells
Bankoti, J., Rase, B., Simones, T., & Shepherd, D. M. (2010) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2010.03.013 · Cited by 136
Evolution of Vertebrate Indoleamine 2,3-Dioxygenases
Yuasa, H., Takubo, M., Takahashi, A., Hasegawa, T., Noma, H., & Suzuki, T. (2007) · Journal of Molecular Evolution · doi:10.1007/s00239-007-9049-1 · Cited by 134
Ribatti, D., Vacca, A., Nico, B., Roncali, L., & Dammacco, F. (2001) · Mechanisms of Development · doi:10.1016/s0925-4773(00)00522-0 · Cited by 128
Pantouris, G., Serys, M., Yuasa, H. J., Ball, H. J., & Mowat, C. G. (2014) · Amino Acids · doi:10.1007/s00726-014-1766-3 · Cited by 127
Mougiakakos, D., Jitschin, R., von Bahr, L., Poschke, I. C., Gary, R., Sundberg, B., Gerbitz, A., Ljungman, P. T., & Blanc, K. L. (2012) · Leukemia · doi:10.1038/leu.2012.215 · Cited by 126
Salter, M., Hazelwood, R., Pogson, C. I., Iyer, R., & Madge, D. J. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00006-l · Cited by 119
Marrying Immunotherapy with Chemotherapy: Why Say IDO?
Muller, A. J., & Prendergast, G. C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2213 · Cited by 117
Muller, A. J., Malachowski, W. P., & Prendergast, G. C. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.4.831 · Cited by 115
Merlo, L. M. F., Pigott, E., DuHadaway, J., Grabler, S., Metz, R., Prendergast, G., & Mandik-Nayak, L. (2014) · Journal of Immunology · doi:10.4049/jimmunol.1303012 · Cited by 110
Tumoral Immune Resistance Mediated by Enzymes That Degrade Tryptophan
van Baren, N., & den Eynde, B. J. V. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0095 · Cited by 101
Jia, Y., Wang, H., Wang, Y., Wang, T., Wang, M., Ma, M., Duan, Y., Meng, X., & Liu, L. (2015) · International Journal of Cancer · doi:10.1002/ijc.29481 · Cited by 98
IDO1 is an Integral Mediator of Inflammatory Neovascularization
Mondal, A., Smith, C., DuHadaway, J. B., Sutanto‐Ward, E., Prendergast, G. C., Bravo‐Nuevo, A., & Muller, A. J. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.11.013 · Cited by 92
Mautino, M. R., Jaipuri, F. A., Waldo, J. P., Kumar, S., Adams, J., Allen, C. V., Marcinowicz-Flick, A., Munn, D. H., Vahanian, N. N., & Link, C. J. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-491 · Cited by 86
Larkin, P. B., Sathyasaikumar, K. V., Notarangelo, F. M., Funakoshi, H., Nakamura, T., Schwarcz, R. M., & Muchowski, P. J. (2016) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2016.07.002 · Cited by 83
Consequences of AhR Activation in Steady-State Dendritic Cells
Simones, T., & Shepherd, D. M. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq354 · Cited by 73
Biochemical characteristics and inhibitor selectivity of mouse indoleamine 2,3-dioxygenase-2
Austin, C. J. D., Mailu, B. M., Maghzal, G., Sánchez-Pérez, Á., Rahlfs, S., Zocher, K., Yuasa, H., Arthur, J. W., Becker, K., Stocker, R., et al. (2010) · Amino Acids · doi:10.1007/s00726-010-0475-9 · Cited by 71
SOCS3 is an endogenous inhibitor of pathologic angiogenesis
Stahl, A., Joyal, J., Chen, J., Sapieha, P. S., Juan, A. M., Hatton, C. J., Pei, D. T., Hurst, C. G., Seaward, M. R., Krah, N. M., et al. (2012) · Blood · doi:10.1182/blood-2012-04-422527 · Cited by 71
Trabanelli, S., Očadlíková, D., Ciciarello, M., Salvestrini, V., Lecciso, M., Jandus, C., Metz, R. A., Evangelisti, C., Laury‐Kleintop, L. D., Romero, P. J., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1300720 · Cited by 69
BAR the door: Cancer suppression by amphiphysin-like genes
Prendergast, G. C., Muller, A. J., Ramalingam, A., & Chang, M. Y. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.09.001 · Cited by 68
Self-citationImmunotherapeutic Suppression of Indoleamine 2,3-Dioxygenase and Tumor Growth with Ethyl Pyruvate
Muller, A. J., DuHadaway, J. B., Jaller, D., Curtis, P. J., Metz, R. A., & Prendergast, G. C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3613 · Cited by 65
Wu, J., Lin, S., Liao, F.-Y., Hsiao, W., Lee, L.-C., Peng, Y., Hsieh, C., Wu, M.-H., Song, J., Yueh, A., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00921 · Cited by 62
Antitumour agents as inhibitors of tryptophan 2,3-dioxygenase
Pantouris, G., & Mowat, C. G. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.11.037 · Cited by 62
IDO2 Modulates T Cell–Dependent Autoimmune Responses through a B Cell–Intrinsic Mechanism
Merlo, L. M. F., DuHadaway, J. B., Grabler, S., Prendergast, G. C., Muller, A. J., & Mandik‐Nayak, L. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600141 · Cited by 62
Eldredge-Hindy, H., DeNittis, A. S., DuHadaway, J. B., Chernick, M. R., Metz, R. A., & Prendergast, G. C. (2013) · Journal of Radiation Oncology · doi:10.1007/s13566-013-0111-x · Cited by 60
Gangadhar, T. C., Hamid, O., Smith, D. C., Bauer, T. M., Wasser, J. S., Olszanski, A. J., Luke, J. J., Balmanoukian, A. S., Kaufman, D. R., Zhao, Y., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw379.06 · Cited by 58
Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2
Bakmiwewa, S. M., Fatokun, A. A., Tran, A., Payne, R. J., Hunt, N. H., & Ball, H. J. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.10.010 · Cited by 57
Therapeutic antibody targeting of indoleamine-2,3-dioxygenase (IDO2) inhibits autoimmune arthritis
Merlo, L. M. F., Grabler, S., DuHadaway, J. B., Pigott, E., Manley, K., Prendergast, G. C., Laury‐Kleintop, L. D., & Mandik‐Nayak, L. (2017) · Clinical Immunology · doi:10.1016/j.clim.2017.01.016 · Cited by 48
1,2,3-Triazoles as inhibitors of indoleamine 2,3-dioxygenase 2 (IDO2)
Röhrig, U. F., Majjigapu, S. R., Caldelari, D., Dilek, N., Reichenbach, P., Ascenção, K., Irving, M. B., Coukos, G., Vogel, P., Zoete, V., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.07.031 · Cited by 42
Role of IL-6 in systemic angiogenesis of the lung
McClintock, J. Y., & Wagner, E. M. (2005) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00006.2005 · Cited by 38
Li, J., Li, Y., Yang, D., Hu, N., Zhanling, G., Kuang, C., & Yang, Q. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.07.013 · Cited by 38
Spahn, J. H., Peng, J., Lorenzana, E. G., et al. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-3-s2-p303 · Cited by 28
Epigenetic inactivation of the tumor suppressor BIN1 drives proliferation of SNF5-deficient tumors
McKenna, E. S., Tamayo, P., Cho, Y., Tillman, E. J., Mora‐Blanco, E. L., Sansam, C. G., Koellhoffer, E. C., Pomeroy, S. L., & Roberts, C. W. M. (2012) · Cell Cycle · doi:10.4161/cc.20280 · Cited by 27
Muller, A., Mandik-Nayak, L., & Prendergast, G. (2010) · Immunotherapy · doi:10.2217/imt.10.22 · Cited by 26
Palmer, G. M., Tiran, Z., Zhou, Z., Capozzi, M. E., Park, W., Coletta, C., Pyriochou, A., Kliger, Y., Levy, O., Borukhov, I., et al. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01677.x · Cited by 18
Malachowski, W. P., Metz, R., Prendergast, G. C., & Muller, A. J. (2005) · Drugs of the Future · doi:10.1358/dof.2005.030.09.918200 · Cited by 15
Prendergast, G. C., & Metz, R. A. (2012) · OncoImmunology · doi:10.4161/onci.21358 · Cited by 14
IDO in Inflammatory Programming and Immune Suppression in Cancer
Prendergast, G. C., Smith, C., Thomas, S., Mandik‐Nayak, L., Laury‐Kleintop, L. D., Metz, R. A., & Muller, A. J. (2014) · Springer eBooks · doi:10.1007/978-1-4899-8056-4_11 · Cited by 8
Cited by
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
Platten, M., Nollen, E. A. A., Röhrig, U. F., Fallarino, F., & Opitz, C. A. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0016-5 · Cited by 1,586
Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion
Leone, R. D., Zhao, L., Englert, J. M., Sun, I.-M., Oh, M.-H., Sun, I.-H., Arwood, M. L., Bettencourt, I. A., Patel, C. H., Wen, J., et al. (2019) · Science · doi:10.1126/science.aav2588 · Cited by 1,169
Long, G. V., Dummer, R., Hamid, O., Gajewski, T. F., Caglevic, C., Dalle, S., Arance, A., Carlino, M. S., Grob, J.-J., Kim, T. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30274-8 · Cited by 960
Cold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 682
Fucikova, J., Spisek, R., Kroemer, G., & Galluzzi, L. (2021) · Cell Research · doi:10.1038/s41422-020-0383-9 · Cited by 400
Metadata
- Venue
- International Review of Cell and Molecular Biology
- Publisher
- Elsevier
- Published
- 2018
- Volume
- 336
- Pages
- 175-203
- ISSN
- 0074-7696 (ISSN-L)
- 1937-6448
- OpenAlex
- W2756621521
- Cited by
- 270
- References
- 114
- FWCI
- 54.79
- Type
- book chapter
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.